|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date25 Aug 2021 |
/ Not yet recruitingPhase 3 A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults with Growth Hormone Deficiency
/ RecruitingNot Applicable A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin)
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
/ RecruitingNot Applicable A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
100 Clinical Results associated with Ascendis Pharma Endocrinology Division A/S
0 Patents (Medical) associated with Ascendis Pharma Endocrinology Division A/S
100 Deals associated with Ascendis Pharma Endocrinology Division A/S
100 Translational Medicine associated with Ascendis Pharma Endocrinology Division A/S